Clinical Trials

The Doctors at VRA are dedicated to providing the best, most up-to-date treatments for our patients. To this end, our doctors have participated in several clinical trials testing new drugs for Age-Related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusions, Vitreomacular Traction, and Ocular Melanoma.

Listed below are the active trials in which we are participating.  Some of these trials are actively enrolling patients and others have completed enrollment and the patients are in the follow-up stage of the trial.  Click on the name of the study to see more information about that specific study.  If you would like to learn more about any of these trials, please send your questions to r.gagnon@proliancesurgeons.com or call our study coordinator at 206.215.3561.

Please note that all of our trials have strict inclusion and exclusion criteria that limit our ability to enroll some of our patients.

GX29185 (Spectri) (Dry macular degeneration) – ACTIVE, ENROLLMENT CLOSED (Genentech)

A phase 3, randomized, double-masked, placebo-controlled trial to assess the safety and efficacy of intravitreal lampalizumab administered intravitreally to patients with bilateral geographic atrophy secondary to age-related macular degeneration.  To be eligible for this study, you must be 50 years of age or older and have a diagnosis of geographic atrophy in both eyes.  If you have any history of wet macular degeneration in either eye, you will not be eligible for the study.  This is a two-year study requiring monthly visits to our Bellevue clinic.

OPH1004 (Wet macular degeneration) – ACTIVE, ENROLLMENT CLOSED (Ophthotech)

This is a phase 3, randomized, double-masked, placebo-controlled trial to establish the safety and efficacy of intravitreal Fovista administered in combination with either Eylea or Avastin, compared to Eylea or Avastin monotherapy in subjects with wet age-related macular degeneration (AMD).  To be eligible for this study, you must be 50 years of age or older and have at least one eye with wet AMD which has not been treated.  All subjects will be randomized to receive either Eylea or Avastin in combination with Fovista, or Eylea or Avastin plus a sham (placebo) injection.  This is a two-year study requiring monthly visits to our Bellevue clinic.

RTH258 (HAWK) (Wet macular degeneration) – ACTIVE, ENROLLMENT CLOSED (Alcon)

A phase 3, randomized, double-masked trial comparing the efficacy and safety of RTH258 versus aflibercept (Eylea) in subjects with wet age-related macular degeneration (AMD).  To be eligible for this study, you must be 50 years of age or older and have at least one eye with wet AMD which has not been treated.  All subjects will be randomized to receive either intravitreal RTH258 or intravitreal Eylea.  This is a two-year study requiring monthly visits to our Bellevue clinic.

SEQUOIA (Wet macular degeneration) – ACTIVE, ENROLLMENT CLOSED (Allergan)

A phase 3, randomized, double-masked trial comparing the efficacy and safety of abicipar compared with ranibizumab (Lucentis) in subjects with wet age-related macular degeneration (AMD).  Subjects must be 50 years of age or older and have at least one eye with wet AMD which has not been treated.  All subjects will be randomized to receive either intravitreal abicipar or intravitreal Lucentis.  This is a two-year study requiring monthly visits to our Bellevue clinic.